

Amendments to the Claims:

1. (Currently Amended) The use of A method for preventing or treating vascular thrombosis, which comprises administering to a subject a medicinal product comprising a sulfated polysaccharide which can be obtained by radical depolymerization of a crude fucan derived from Phaeophyceae, said polysaccharide having a molar mass of less than or equal to 10,000 g/mol , for producing a medicinal product intended to prevent or treat vascular thrombosis.

2. (Currently Amended) The use method as claimed in claim 1, characterized in that wherein said medicinal product is intended to prevent or treat venous thrombosis.

3. (Currently Amended) The use method as claimed in claim 1, characterized in that wherein said medicinal product is intended to prevent or treat arterial thrombosis.

4. (Currently Amended) The use method as claimed in claim 3, for preventing arterial restenosis.

5. (Currently Amended) The use method as claimed in any one of claims 1 to 4, characterized in that claim 1, wherein said sulfated polysaccharide has a molar mass of less than 5000 g/mol.

6. (Currently Amended) The use method as claimed in any one of claims 1 to 5, characterized in that claim 1, wherein said medicinal product is intended to be administered parenterally.

7. (Currently Amended) The use method as claimed in claim 6, characterized in that wherein said medicinal product is intended to be administered intravenously.

8. (Currently Amended) The use method as claimed in claim 6, characterized in that wherein said medicinal product is intended to be administered subcutaneously.

9. (Currently Amended) The use method as claimed in claim 8, ~~characterized in that wherein~~ said medicinal product is ~~intended to be~~ administered, preventatively, at a daily dose of between 150 and 300 mg.

10. (Currently Amended) The use method as claimed in claim 8, ~~characterized in that wherein~~ said medicinal product is ~~intended to be~~ administered, curatively, at a daily dose of between 450 and 600 mg.

11. (Currently Amended) The use method as claimed in claim 4, ~~characterized in that wherein~~ said medicinal product is ~~intended to be~~ administered locally.

12. (Currently Amended) The use method as claimed in claim 11, ~~characterized in that wherein~~ said medicinal product is ~~intended to be~~ administered by endoparietal diffusion.